Delta, Kelowna, BC –July 15, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at Investor Ideas Potcasts, Cannabis News and Stocks on the Move July 15 (NYSE: ACB) (TSX: ACB.TO) (TSXV: EMH) (TSX: ALEF.TO) (CSE: CSI.C) (OTC: TSOI) (CSE: AGRO.C)
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
The new sites in Quebec and British Columbia will be used for cultivation research to develop new technology, genetics and intellectual property in order to drive sustainable, high-quality outdoor production. Aurora purposefully chose the outdoor sites because they represent two different growing environments. The company will conduct research on cultivation techniques to further excel at growing cannabis in varying climate conditions and will examine approaches to environmentally sustainable cannabis agriculture.
The newly-named Western facility will be called Aurora Valley and is a 207-acre operation in Westwold, British Columbia. The Eastern facility, a 21,000 square foot operation at the Aurora Eau facility in Lachute, is the first approved outdoor grow operation for cannabis in Quebec. Aurora Valley is expected to be planted shortly and Aurora Eau has already been planted.
The two sites are an extension of the scientific research Aurora will be conducting at its new Comox facility, which will be ready in the fall of 2019. The Comox facility consists of a 21,000 square foot indoor grow facility and a 10,500 square foot laboratory. This unique research centre will be home for Aurora's plant breeding team designed to create new cannabis cultivars with improved growing characteristics for both indoor and outdoor cultivation.
"Aurora believes in innovative operations and intensive research and we're applying our approach to outdoor grown cannabis," said Aurora CEO Terry Booth. "Our team plans to use these areas to ensure we are able to consistently grow the high-quality cannabis Aurora has become known for around the world. We're proud to be a Canadian company and this is a further commitment to research and job creation in Canada."
Dr. Jonathan Page, Chief Science Officer at Aurora added, "For this season and next, our focus will be on researching cultivation methods and evaluating genetics in order to produce high THC and CBD cannabis in outdoor-grown plants, with the ultimate goal of extracting these components. The unique climates of each site also presents a great opportunity to determine which cultivars will perform best in different outdoor environments."
In addition to the two new outdoor production sites, Aurora confirms it has now received the Health Canada processing license for its Aurora Air facility located near the Edmonton International Airport and Aurora Sky. Aurora Air will be home to several of the new production lines for edible products such as gummies and chocolates, to be introduced to the Canadian consumer market in December 2019.
Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) has received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, BC. The outdoor grow area is expected to be capable of producing approximately 10,000 kg of cannabis annually with multiple crops during a full growing season. With this license effective as of July 12, 2019, Emerald is positioned to deliver one harvest and a portion of the expected full production volume this year.
The 12 acres (~500,000 square feet) of outdoor cultivation are part of an overall 20-acre site that includes 156,000 sq. ft. in two greenhouses. This operation was purposefully designed for organic cultivation with the goal of exceeding 20,000 kg of annual production. There is also the prospect of securing and licensing an additional adjacent 12 acres of outdoor grow area, with potential for an additional approximately 10,000 kg of annual production.
“As one of the few licensed producers licensed for outdoor growing, receiving this cultivation license highlights our planning and execution to achieve potentially very-low cost organic cannabis. We have been working for months on ground and seed preparation and are now preparing for planting,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald. “With our team’s extensive organic farming experience and expertise, we look forward to assessing multiple cannabis strains and refining cultivation practices for scalable outdoor growing.”
With the organic operation’s first greenhouse ready for cultivation and the second greenhouse near completion, Emerald will continue to apply for license amendments to expand its licensed cultivation areas. Emerald is also working to complete the requirements for municipal permitting.
Separately, Health Canada also approved Emerald’s amendment application to increase its processing footprint at one of its two Victoria, British Columbia facilities, allowing Emerald to expand processing and storage capabilities.
Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) announced that on July 12, 2019, Aleafia Health’s wholly-owned subsidiary, Aleafia Farms Inc., secured a License Amendment under Health Canada’s Cannabis Regulations authorizing cannabis cultivation for the entirety of the Company’s Port Perry Outdoor Grow facility. The Licence immediately increases the Company’s licensed and operational outdoor cultivation area from 292,000 sq. ft. to over 1.1 million sq. ft.
As previously announced on June 10, 2019, Aleafia Farms received approval for cultivation in Zone 1 of the Outdoor Grow facility, and days later completed the planting of Canada’s first legal, large-scale outdoor crop. The License now adds Zones 2, 3 and 4 which encompasses the full 1.1 million sq. ft. cultivation area. The License is effective as of July 12, 2019 and expires on October 13, 2020.
The Company expects to commence planting the newly licensed area on July 15, 2019, using approximately 7,000 cannabis plants currently growing in pots in Zone 1. The Outdoor Grow operation will be overseen by Aleafia Health’s proven, experienced cultivation team, which together have led the build-out and operations of seven cannabis cultivation facilities.
“The immediate four-fold increase in Aleafia Health’s licensed and operational cultivation area is our most significant milestone to date,” said Aleafia Health Chairman Julian Fantino. “We will continue to lead the way in low-cost production. This exponentially increases our total cultivation footprint while securing and increasing product supply for medical cannabis patients.”
It is intended that the cannabis grown at the Company’s Outdoor Grow facility will be processed at the Company’s Paris Facility, for the extraction and production of high-margin products within a closed loop ecosystem.
“Our team is again relentlessly focused on execution, with plants in the ground within one business day of receiving our new Health Canada licence,” said Aleafia Health CEO Geoffrey Benic. “We plan to benefit from the increasing scale of our production operations across three facilities. Low-cost cannabis grown at Port Perry will accelerate and scale our mission of growing, producing and selling high-margin value-added cannabis health and wellness products globally.”
Chemesis International Inc. (CSE: CSI) (OTC: CADMF) announced a Partnership with U.S. based Happy Tea, a brand of CBD infused sachets and shots, to expand its product offering and realize cost savings by leveraging Chemesis’ extraction, finished goods manufacturing and retail distribution.
Happy Tea currently offers 3 products including powdered drink mixes and flavoured oil shots that are comprised of a blend of all-natural ingredients, antioxidants and are infused with 10mg of CBD. Consumers can purchase these products individually or subscribe to monthly deliveries, which are shipped via the company’s e-commerce sales channels across the United States. Happy Tea will leverage Chemesis’ multi-state operations to increase production capabilities and create retail brick and mortar exposure through the Companies distribution.
Chemesis will assist Happy Tea in expanding its current 3 SKU’s to an expanded product line of 9 SKU’s. The Company will manufacture Happy Tea products in its U.S. based facilities and will increase production as demand rises. As per the Partnership, Chemesis received a $4,000,000 USD minimum purchase order to manufacture products, as demand rises and Happy Tea expands its product catalogue, additional contracts will be added to ensure sufficient supply.
"The production and development capabilities of Chemesis fits in-line with what we’re are always striving to accomplish,” said Jarrod Swanger, COO of Happy Tea. “Every CBD company on the block along with their manufacturers are making creams and drops. We are the only two entities striving to redefine delivery. With their capacity and capability and our branding we will own the CBD market."
“We are extremely pleased to be working with Happy Tea, a developed brand that is currently in a high-growth phase,” said CEO, Edgar Montero. “Happy Tea’s products and vision are something the Company believes in and excited to be supporting its long-term growth. Both Companies are exploring other strategic ways of working together to create mutual synergies that are beneficial to all stakeholders. Chemesis’ will continue its efforts in creating lasting partnerships that bring strong revenues and continued progression.”
Agrios Global Holdings Ltd. (CSE: AGRO) (OTCQB: AGGHF) announced that Onyx Agronomics has substantially reduced their carbon footprint, cutting their energy consumption by 63% and achieving greater yield efficiency by following the growing recommendations made by the Company.
Agrios collects millions of unique data points from the crops over the course of the harvest cycle on a per cultivar basis, and then analyzes this "actionable data" in order to develop effective strategies for optimizing the growing environment and reducing the use of energy, light, and water. Thus, crops are raised sustainably in an environmentally friendly way at a reduced cost.
On the advice of Agrios, the plant density in the growing space is modified and a substantial increase in flower-to-trim ratio has been observed. A simple modification in plant placement increased crop yield efficiency from a 50.5% / 49.5% flower-to-trim ratio to an 81% / 19% flower-to-trim ratio. This results in a higher volume of premium product – an increased yield efficiency at lowered production costs, and increased profitability.
Andrew Lange, Chief Technical Officer, reports that, "Overall production or raw yield doesn't tell the complete story on how a given company is set up to perform financially. There are also several ways to measure crop yield, and some are more effective than others. The most common yield reporting system is grams per square foot (g/sq. ft.) so yields at different facilities can be compared based on productivity. The square footage of the facility is calculated using the canopy of the cultivation area, and product weight should be reported as dry and destemmed."
However, there are no industry regulations or monitoring of how a yield measurement is calculated amongst commercial operators at the present time. There is variance in what is measured as "canopy" space, and product weight could be of an inconsistent product mix.
Lange believes that achieving production and yield efficiency is more important than maximizing raw yield, for several reasons. Large cannabis cultivation facilities have increased operational cost and risk. While such facilities' raw yield may be greater, their production costs are also higher. Companies such as Agrios which have developed production efficiencies and consume less energy or are otherwise environmentally friendly, and have a smaller carbon footprint, are also spending less to create more efficient yields.
Chris Kennedy President & CEO of Agrios stated, "We are pleased to validate the benefits of our technology enabled approach to create a sustainable model, enabling cultivators to be competitive, in these current volatile, compressed markets. We have a strong foundation as we focus on our expansion efforts."
Andrew wrote a detailed explanation of several methods of yield calculation, and the importance of yield efficiency in a June 2019 article for the Cannabis Business Times, entitled Measuring Yield: Why Efficiency Metrics Are Essential. Please visit the link below to view the full article.
Cannabidiol (also known as CBD), a phytocannabinoid derived from the cannabis species, is devoid of psychoactive activity, but has analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms.
The addition of "Nano Cannabidiol" to NanoMyros is to inhibit microvesicles and exosomes from being released by other cells in communication intracellularly through the transfer of proteins. Microvesicle and exosome release has been associated with multiple pathologies, including many cancers, which increases drug resistance and the transfer of other pro-oncogenic factors.
"This final piece of this unique synergistic blend of pterostilbene, glucoraphanin, myrosinase, and now cannabidiol is not available by any other manufacturer that we are aware of and is built entirely on our nano products NanoStilbene and Nano Cannabidiol," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "We will offer the NanoMyros with and without Nano Cannabidiol so as not to restrict anyone from the benefits of NanoPSA and NanoMyros as stand-alone nutraceuticals."
"Preliminary data from our collaborators indicates that this combination is effective at decreasing both production of pathological exosomes, as well as the responsiveness of target cells to pathological exosomes," said Thomas Ichim, Ph.D., Board Member of TSOI. "Specifically, we have demonstrated that subsequent to treatment of cancer cells using the combination product, there was both a decrease in the production of Fas ligand bearing exosomes, which are known to kill immune cells, as well as an increased resistance of immune cells to killing by Fas ligand bearing exosomes produced by cancer."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit:Investorideas.com Investing and trading ideas Podcasts about bitcoin, blockchain, biotech, cannabis, cleantech, sports, mining, tech, support and resistance trading, now on iTunes, Spotify, Google Play Music, iHeart.com, Spreaker, SoundCloud.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles ,podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the dailyCrypto Corner and Podcast,Play by Play sports and stock news column,Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and theAI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: InvestorIdeas - Disclaimer, full disclosure, compensation disclosure Learn more about publishing your news release and our other news services on the Investorideas.com newswire Investorideas.com Newswire press release service-, ticker tag service, podcast news service, Submit stock and business news - be seen on Google News, Apple news, Marketwatch, Financial Content , social media and global RSS syndication and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: www.investorideas.com/... Learn more about publishing your news release and our other news services on the Investorideas.com newswire www.investorideas.com/... and tickertagstocknews.com